SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: DewDiligence_on_SI7/28/2009 1:53:33 AM
  Read Replies (1) of 10345
 
Copaxone vs Tysabri in the US Market 

      Tysabri    Copaxone 
     sales ($M) sales ($M) 
2Q09    125        438 
1Q09    116        430 
4Q08    115        384 
3Q08    122        352
The cumulative growth of US Tysabri sales during the past three quarters has been 2.5%.

The cumulative growth of US Copaxone sales during the past three quarters has been 24.4%.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News